{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:00:51Z","timestamp":1791392451687,"version":"4.3.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-03070-1","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:45:09Z","timestamp":1791391509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Narsoplimab in critically ill patients with high-risk transplant-associated thrombotic microangiopathy requiring intensive care"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3954-4781","authenticated-orcid":false,"given":"AB","family":"Bocanegra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"De Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4519-4090","authenticated-orcid":false,"given":"C.","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Valdenebro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu\u00f1oz-S\u00e1nchez","family":"Ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lipperheide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rez-Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Portol\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5240-9815","authenticated-orcid":false,"given":"RF","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"3070_CR1","doi-asserted-by":"publisher","unstructured":"Carreras E, D\u00edaz-Ricart M, Jodele S, Penack O, Vasu S. Early complications of endothelial origin. In The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies (eds Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E.) 373\u201383 (Springer, 2024). https:\/\/doi.org\/10.1007\/978-3-031-44080-9_42.","DOI":"10.1007\/978-3-031-44080-9_42"},{"key":"3070_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"ML Schoettler","year":"2023","unstructured":"Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023;29:151\u201363. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.015.","journal-title":"Transplant Cell Ther"},{"key":"3070_CR3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40265-026-02328-8","volume":"86","author":"M Shirley","year":"2026","unstructured":"Shirley M. Narsoplimab: first approval. Drugs. 2026;86:1165\u201370. https:\/\/doi.org\/10.1007\/s40265-026-02328-8.","journal-title":"Drugs"},{"key":"3070_CR4","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1200\/JCO.21.02389","volume":"40","author":"SK Khaled","year":"2022","unstructured":"Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, et al. Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy. J Clin Oncol. 2022;40:2447\u201357. https:\/\/doi.org\/10.1200\/JCO.21.02389.","journal-title":"J Clin Oncol"},{"key":"3070_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/bloodadvances.2025017540","volume":"10","author":"H Matsui","year":"2026","unstructured":"Matsui H, Arai Y, Kanda J, Tadakazu K, Michelle LS, Mohamad M, et al. Survival in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis of narsoplimab versus supportive care. Blood Adv. 2026;10:111\u201323. https:\/\/doi.org\/10.1182\/bloodadvances.2025017540.","journal-title":"Blood Adv"},{"key":"3070_CR6","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/ajh.70044","volume":"100","author":"ML Schoettler","year":"2025","unstructured":"Schoettler ML, Pusarla SK, Nangia N, Perales MA, Duarte RF, Grauer A, et al. Narsoplimab results in excellent survival in adults and children with hematopoietic cell transplant associated thrombotic microangiopathy (TA-TMA). Am J Hematol. 2025;100:2040\u201351. https:\/\/doi.org\/10.1002\/ajh.70044.","journal-title":"Am J Hematol"},{"key":"3070_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jtct.2025.05.028","volume":"31","author":"ML Schoettler","year":"2025","unstructured":"Schoettler ML, Gavriilaki E, Carreras E, Bo-Kyoung C, Dandoy CE, Ho VT, et al. An ASTCT, CIBMTR, EBMT, and APBMT consensus statement defining response criteria for hematopoietic cell transplantation-associated thrombotic microangiopathy (TA-TMA)-directed therapy. Transplant Cell Ther. 2025;31:610\u201323. https:\/\/doi.org\/10.1016\/j.jtct.2025.05.028.","journal-title":"Transplant Cell Ther"},{"key":"3070_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1297352","volume":"14","author":"T Dudler","year":"2023","unstructured":"Dudler T, Yaseen S, Cummings WJ. Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders. Front Immunol. 2023;14:1297352. https:\/\/doi.org\/10.3389\/fimmu.2023.1297352.","journal-title":"Front Immunol"},{"key":"3070_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/cei\/uxad055","volume":"213","author":"S Elhadad","year":"2023","unstructured":"Elhadad S, Redmond D, Huang J, Tan A, Laurence J. MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence. Clin Exp Immunol. 2023;213:252\u201364. https:\/\/doi.org\/10.1093\/cei\/uxad055.","journal-title":"Clin Exp Immunol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03070-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03070-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03070-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:45:10Z","timestamp":1791391510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03070-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":9,"alternative-id":["3070"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03070-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For the work presented here, RFD declares honoraria as an advisor and\/or speaker from Jazz Pharmaceuticals, Omeros Corporation and Sobi Pharma. All other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}